Version 1
: Received: 10 October 2023 / Approved: 11 October 2023 / Online: 13 October 2023 (07:09:33 CEST)
How to cite:
Alotaibi, A.B.; Albarrak, D.A.; Alammari, Y. Efficacy and safety of biologics in treating ankylosing spondylitis and their impact on quality of life and comorbidities: a narrative review. Preprints2023, 2023100721. https://doi.org/10.20944/preprints202310.0721.v1
Alotaibi, A.B.; Albarrak, D.A.; Alammari, Y. Efficacy and safety of biologics in treating ankylosing spondylitis and their impact on quality of life and comorbidities: a narrative review. Preprints 2023, 2023100721. https://doi.org/10.20944/preprints202310.0721.v1
Alotaibi, A.B.; Albarrak, D.A.; Alammari, Y. Efficacy and safety of biologics in treating ankylosing spondylitis and their impact on quality of life and comorbidities: a narrative review. Preprints2023, 2023100721. https://doi.org/10.20944/preprints202310.0721.v1
APA Style
Alotaibi, A.B., Albarrak, D.A., & Alammari, Y. (2023). Efficacy and safety of biologics in treating ankylosing spondylitis and their impact on quality of life and comorbidities: a narrative review. Preprints. https://doi.org/10.20944/preprints202310.0721.v1
Chicago/Turabian Style
Alotaibi, A.B., Danah Abdullah Albarrak and Yousef Alammari. 2023 "Efficacy and safety of biologics in treating ankylosing spondylitis and their impact on quality of life and comorbidities: a narrative review" Preprints. https://doi.org/10.20944/preprints202310.0721.v1
Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that affects the axial skeleton, causing intense pain, progressive joint destruction, and a gradual reduction in physical function. It has been recognized not only as affecting the axial skeleton but as a systemic disease. Since it also causes an increase in the rates of inflammatory bowel disease, psoriasis, acute anterior uveitis, and mental disorders affecting the quality of life. Furthermore, an association with neurological and cardiovascular events is documented. With the advent of biologics, treating AS dramatically changed due to its high efficacy and tolerable safety. AS can be treated with various biological treatments. Nevertheless, there are differences in traits, including rapidity of onset, long-term efficacy, safety profile, and influence on comorbidities. A better understanding of such traits enables clinicians to make the best decision for each patient, increasing persistence, extending medication survival, enhancing patient satisfaction, and reducing the disease effect of ankylosing spondylitis. In this article, we emphasize biologics' efficacy and safety profile in patients with ankylosing spondylitis. In addition, we discuss the impact of biologics on comorbidities and health-related quality of life.
Keywords
efficacy and safety, ankylosing spondylitis; biologics; quality of life.
Subject
Medicine and Pharmacology, Clinical Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
